Congressional Research Service Reports - 555 Matching Results
Search Results
- The Changing Demographic Profile of the United States
- As noted by the Population Reference Bureau, “The U.S. is getting bigger, older, and more diverse.” The objective of this report is to highlight some of the demographic changes that have already occurred since 1950 and to illustrate how these and future trends will reshape the nation in the decades to come (through 2050). This report discusses the current and projected demographic changes if policymakers accelerate efforts to address and adapt to the changing population profile as it relates to a number of essential domains, such as work, retirement, and pensions, private wealth and income security, and the health and well-being of the aging population.
- Cloning: A Select Chronology, 1997-2003
- This report includes a selected chronology of the events surrounding and following the cloning of a sheep from a single adult sheep cell by Scottish scientists, which was announced in February 1997. The project was cosponsored by PPL Therapeutics, Edinburgh, Scotland, which has applied for patents for the techniques used. This chronology also addresses subsequent reports of other cloning experiments, including the first one using human cells. Information on presidential actions and legislative activities related to the ethical and moral issues surrounding cloning is provided, as well as relevant Web sites.
- Cloning: A Select Chronology, 1997-2003
- This report includes a selected chronology of the events surrounding and following the cloning of a sheep from a single adult sheep cell by Scottish scientists, which was announced in February 1997. The project was cosponsored by PPL Therapeutics, Edinburgh, Scotland, which has applied for patents for the techniques used. This chronology also addresses subsequent reports of other cloning experiments, including the first one using human cells. Information on presidential actions and legislative activities related to the ethical and moral issues surrounding cloning is provided, as well as relevant Web sites.
- Cloning: A Select Chronology, 1997-2003
- This report includes a selected chronology of the events surrounding and following the cloning of a sheep from a single adult sheep cell by Scottish scientists, which was announced in February 1997. The project was cosponsored by PPL Therapeutics, Edinburgh, Scotland, which has applied for patents for the techniques used. This chronology also addresses subsequent reports of other cloning experiments, including the first one using human cells. Information on presidential actions and legislative activities related to the ethical and moral issues surrounding cloning is provided, as well as relevant Web sites.
- Cloning: Where Do We Go From Here?
- News in February 1997 that scientists in Scotland had succeeded in cloning an adult sheep ignited a worldwide debate. Of concern are the ethical and social implications of the potential application of cloning to produce human beings. In response to concerns about the potential application of cloning to produce humans, actions were taken by the Administration and Congress.
- Coal Excise Tax Refunds: United States v. Clintwood Elkhorn Mining Co.
- In 1998, a U.S. district court held that the imposition of the coal excise tax, or black lung excise tax, on coal destined for export was unconstitutional. The process of refunding the tax has been controversial. This is because some coal producers and exporters have attempted to bypass the limitations in the Internal Revenue Code's refund scheme for bringing suit under the Export Clause in the Court of Federal Claims, seeking damages from the United States in the amount of coal excise taxes paid. The Federal Circuit Court of Appeals held the court had jurisdiction under the Tucker Act to hear the suits and allowed them as an alternative to the Code's refund process. However, in a 2008 decision, United States v. Clintwood Elkhorn Mining Co., the Supreme Court unanimously held that taxpayers must comply with the Code's administrative refund process before bringing suit. Meanwhile, H.R. 1762 and S. 373 would provide an alternative method for taxpayers to receive coal excise tax refunds.
- Community mental health centers
- This report provides information about community health centers which treat mentally ill persons in their own community.
- Comparison of the Current World Trade Center Medical Monitoring and Treatment Program and the World Trade Center Health Program Proposed by Title I of H.R. 847
- This report compares the current federally supported medical screening and treatment program offered to various persons affected by the terrorist attack on New York City on September 11, 2001, with the federal program proposed to be established by Title I of H.R. 847, the James Zadroga 9/11 Health and Compensation Act of 2010, as amended and passed by the House of Representatives. The World Trade Center (WTC) Medical Monitoring and Treatment Program (MMTP) and the World Trade Center Health Program (WTCHP) are the specific programs compared in this report.
- Comparison of the Current World Trade Center Medical Monitoring and Treatment Program and the World Trade Center Health Program Proposed by Title I of H.R. 847
- This report compares the current federally supported medical screening and treatment program offered to various persons affected by the terrorist attack on New York City on September 11, 2001, with the federal program proposed to be established by Title I of H.R. 847, the James Zadroga 9/11 Health and Compensation Act of 2010, as amended and passed by the House of Representatives. The World Trade Center (WTC) Medical Monitoring and Treatment Program (MMTP) and the World Trade Center Health Program (WTCHP) are the specific programs compared in this report.
- Comparison of the Current World Trade Center Medical Monitoring and Treatment Program and the World Trade Center Health Program Proposed by Title I of H.R. 847
- This report compares the current federally supported medical screening and treatment program offered to various persons affected by the terrorist attack on New York City on September 11, 2001, with the federal program proposed to be established by Title I of H.R. 847, the James Zadroga 9/11 Health and Compensation Act of 2010, as amended and passed by the House of Representatives.
- Comparison of the Current World Trade Center Medical Monitoring and Treatment Program and the World Trade Center Health Program Proposed by Title I of H.R. 847
- This report compares the current federally supported medical screening and treatment program offered to various persons affected by the terrorist attack on New York City on September 11, 2001, with the federal program proposed to be established by Title I of H.R. 847, the James Zadroga 9/11 Health and Compensation Act of 2010, as amended and passed by the House of Representatives. The World Trade Center (WTC) Medical Monitoring and Treatment Program (MMTP) and the World Trade Center Health Program (WTCHP) are the specific programs compared in this report.
- Compensating Farmers for the Tobacco Settlement
- The legislative proposals designed to reduce smoking, primarily by teenagers, are likely to have negative economic consequences for tobacco growers and tobacco-dependent communities. This report discusses the possibility of some kind of compensation to farmers as part of the settlement package legislation.
- Compliance with the HIPAA Medical Privacy Rule
- As of April 14, 2003, most health care providers (including doctors and hospitals) and health plans are required to comply with the new Privacy Rule mandated by the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), and must comply with national standards to protect individually identifiable health information. The HIPAA Privacy Rule creates a federal floor of privacy protections for individually identifiable health information; establishes a set of basic consumer protections; institutes a series of regulatory permissions for uses and disclosures of protected health information; permits any person to file an administrative complaint for violations; and authorizes the imposition of civil or criminal penalties.
- The Cost of Prescription Drugs for the Uninsured Elderly and Legislative Approaches
- The purpose of this report is to explain why many of those who are least able to afford high drug costs are those who are most frequently charged the most. This report describes the basic economic theory underlying price differentiation and, in the context of the pharmaceutical market, analyzes the role and behavior of pharmacy benefit managers (PBMs), pharmaceutical manufacturers, and retail pharmacies, respectively. It also looks at a number of the criticisms that have been made of the practice of differential pricing. Finally, this report discusses various policy approaches aimed at assisting the elderly to purchase prescription drugs.
- CRISPR Gene Editing Research in Embryos Generates Scientific and Ethics Debate
- This report discusses the results of a recent experiment on the use of gene modification for decreasing the chance of children having hypertrophic cardiomyopathy which was done through the use of CRISPR to modify the genes of human embryos at a private facility. Restrictions on the use of public funds for such studies, a brief explanation of the science, and ethical concerns are discussed.
- Critical Infrastructure: The National Asset Database
- The purpose of this report is to discuss the National Asset Database: what is in it, how it is populated, what the Database apparently is, what it is not, and how it is intended to be used. The report also discusses some of the issues on which Congress could focus its oversight, including appropriation bill language.
- Direct-to-Consumer Advertising of Prescription Drugs
- The Direct-to-Consumer advertising of perscription drugs by pharmaceutical companies has been described as any promotional effort with respect to these drugs that targets the general public through the lay media. This report contains information on growth in spending on direct-to-consumer prescription drug advertising, the impact of such advertising, the FDA's existing authority to regulate such advertising, funding, and legislative issues.
- Direct-to-Consumer Advertising of Prescription Drugs
- This report describes the current status of direct-to-consumer (DTC) drug advertising; analyzes issues surrounding it; and discusses potential options for Congress.
- Disease Funding and NIH Priority Setting
- Research at the National Institutes of Health (NIH) has strong political support, but a heated debate rages over the allocation of NIH funds among various diseases. NIH contends that decisions are made based on scientific opportunity while critics of the NIH process charge that spending often follows current politics and political correctness.
- DNA Databanking: Selected Fourth Amendment Issues and Analysis
- This report looks at how the practice of DNA database programs, which have been looked at favorably by Congress, are in possible violation of the Fourth Amendment's prohibition on unreasonable searches and seizures. It looks at how the databases' legality has currently been holding up in court, as well as how new advances and revelations in the science of forensic analysis and databanking may have potentially significant legal implications.
- DNA Evidence: Legislative Initiatives in the 106th Congress
- DNA evidence is a powerful forensic tool in criminal cases. Its use and capabilities have increased substantially since it was first introduced in the late 1980s. That growth has led to the emergence of the following issues that were considered by the 106th Congress in legislative initiatives: eliminating the nationwide backlog of unanalyzed DNA samples, expanding the kinds of offenders who are profiled, providing opportunities for post-conviction testing of DNA evidence, and continuing development of forensic science capabilities. This report discusses those and related issues and the legislation proposed and enacted to address them. It begins by describing provisions in prior federal law and then discusses issues and the legislation proposed, including the enacted DNA Analysis Backlog Elimination Act of 2000 (H.R. 4640, which became P.L. 106-546).
- DNA Testing for Law Enforcement: Legislative Issues for Congress
- DNA evidence is a powerful forensic tool in criminal cases. Its use and capabilities have increased substantially since it was first introduced in the late 1980s. That growth has led to the emergence of the following issues that were considered by the 106th Congress in legislative initiatives: eliminating the nationwide backlog of unanalyzed DNA samples, expanding the kinds of offenders who are profiled, providing opportunities for post-conviction testing of DNA evidence, and continuing development of forensic science capabilities. This report discusses those and related issues and the legislation proposed and enacted to address them. It begins by describing provisions in prior federal law and then discusses issues and the legislation proposed, including the enacted DNA Analysis Backlog Elimination Act of 2000 (H.R. 4640, which became P.L. 106-546).
- "Don't Ask, Don't Tell": Military Policy and the Law on Same-Sex Behavior
- This report describes the "Don't Ask, Don't Tell" military policy, which holds that the presence in the armed forces of persons who demonstrate a propensity or intent to engage in same-sex acts would create an unacceptable risk to the high standards of morale, good order and discipline, and unit cohesion which are the essence of military capability. Under this policy, but not the law, service members are not to be asked about nor allowed to discuss their "same-sex orientation." This report also describes recent efforts by certain Members of Congress to amending this policy.
- "Don't Ask, Don't Tell": The Law and Military Policy on Same-Sex Behavior
- This report describes the "Don't Ask, Don't Tell" military policy, which holds that the presence in the armed forces of persons who demonstrate a propensity or intent to engage in same-sex acts would create an unacceptable risk to the high standards of morale, good order and discipline, and unit cohesion which are the essence of military capability. Under this policy, but not the law, service members are not to be asked about nor allowed to discuss their "same-sex orientation." This report also describes recent efforts by certain Members of Congress to amending this policy.
- "Don't Ask, Don't Tell:" The Law and Military Policy on Same-Sex Behavior
- This report describes the "Don't Ask, Don't Tell" military policy. Under this policy, but not the law, service members are not to be asked about nor allowed to discuss their "same-sex orientation." This report also describes recent efforts by certain Members of Congress to amending this policy.
- "Don't Ask, Don't Tell": The Law and Military Policy on Same-Sex Behavior
- This report describes the "Don't Ask, Don't Tell" military policy, which holds that the presence in the armed forces of persons who demonstrate a propensity or intent to engage in same-sex acts would create an unacceptable risk to the high standards of morale, good order and discipline, and unit cohesion which are the essence of military capability. This report also describes recent efforts by certain Members of Congress to amending this policy.
- Drug abuse office and treatment act of 1972(s.2097; P.L 92-255):Summary of major provisions
- This report addresses the drug abuse office and treatment act of 1972.
- Drug Control
- How to prevent the non-medical use of dependency-producing drugs has been a public policy concern for at least a century. A large part of the responsibility for controlling such substances has been assumed by the Federal Government. Historically based on decision to restrict availability through a system of close regulation, including selective prohibition, the current Federal anti-drugs strategy lives on activities and programs in five major areas: 1) regulation and other “enforcement” efforts; 2) support for international control and for control efforts of individual drug-producing and drug-transiting countries; 3) education and other prevention activities; 4 ) treatment and rehabilitation for drug-dependent persons; and ( 5 ) research on drugs , drug dependency, and prevention and treatment methods.
- Ebola: 2014 Outbreak in West Africa
- This report gives a overview of the West African Ebola outbreak that began in March, 2014. The report discusses the nature of the disease as well as local and international responses to it. The report also briefly examines U.S policy and congressional actions in the wake of the outbreak.
- Ecstasy: Actions of the 107th Congress to Control MDMA
- Legislation has been proposed in the 107th Congress to combat the use and abuse of Ecstasy (MDMA) and other “club drugs.” In a 2001 survey, 12% of 12th graders reported ever having taken the drug. The Ecstasy Anti-Proliferation Act of 2000, enacted by the 106th Congress, directed the U.S. Sentencing Commission to increase penalties for Ecstasy offenses. As of March 2001, MDMA penalties became more severe than for powder cocaine but less severe than for heroin.
- Ecstasy: Actions of the 107th Congress to Control MDMA
- Legislation has been proposed in the 107th Congress to combat the use and abuse of Ecstasy (MDMA) and other “club drugs.” In a 2001 survey, 12% of 12th graders reported ever having taken the drug. The Ecstasy Anti-Proliferation Act of 2000, enacted by the 106th Congress, directed the U.S. Sentencing Commission to increase penalties for Ecstasy offenses. As of March 2001, MDMA penalties became more severe than for powder cocaine but less severe than for heroin.
- Ecstasy: Actions of the 107th Congress to Control MDMA
- Legislation has been proposed in the 107th Congress to combat the use and abuse of Ecstasy (MDMA) and other “club drugs.” In a 2001 survey, 12% of 12th graders reported ever having taken the drug. The Ecstasy Anti-Proliferation Act of 2000, enacted by the 106th Congress, directed the U.S. Sentencing Commission to increase penalties for Ecstasy offenses. As of March 2001, MDMA penalties became more severe than for powder cocaine but less severe than for heroin.
- Ecstasy: Legislative Proposals in the 107th Congress to Control MDMA
- Legislation has been proposed in the 107th Congress to combat the use and abuse of Ecstasy (MDMA) and other “club drugs.” In a 2001 survey, 12% of 12th graders reported ever having taken the drug. The Ecstasy Anti-Proliferation Act of 2000, enacted by the 106th Congress, directed the U.S. Sentencing Commission to increase penalties for Ecstasy offenses. As of March 2001, MDMA penalties became more severe than for powder cocaine but less severe than for heroin.
- Emergency Response: Civil Liability of Volunteer Health Professionals
- This report discusses the patchwork of federal and state laws that operate to protect volunteers, which can include volunteer health professionals (VHPs), and those laws that trigger liability protection only for VHPs — with a focus on some of the midwestern states in addition to the Gulf region.
- End-of-Life Care: Services, Costs, Ethics, and Quality of Care
- This report provides information on various aspects of end-of-life care: (1) demographic and historical changes affecting death and dying in the United States (2) the definitions of end-of-life, palliative, and hospice care (3) costs associated with end-of-life care (4) end-of-life care laws and ethics (5) quality of care at the end of life and (6) policy issues that would modify or expand the federal government's role in addressing end-of-life care.
- Endocrine Disruption: An Introduction
- Exposure to certain chemicals in the environment could disrupt the hormone systems of animals and humans, according to some scientists who are concerned about potential risks to public health and ecosystems. Congress has mandated chemical screening to assess the potential of pesticides and drinking water contaminants to influence the normal functions of female, male and thyroid hormones. As conflicting scientific evidence accumluates on the hormone disruption hypothesis, legislators may consider proposals to increase or decrease funding for the endocrine disruption screening program, or to expand its requirements to include additional chemicals or hormone functions.
- Ergonomics in the Workplace: Is It Time for an OSHA Standard?
- Improper ergonomic design of jobs is one of the leading causes of work-related illness, accounting for perhaps a third of employers’ costs under state workers’ compensation laws. Due to the wide variety of circumstances, however, any comprehensive standard would probably have to be complex and costly, while scientific understanding of the problem is not complete.
- Ergonomics in the Workplace: Is It Time for an OSHA Standard?
- Improper ergonomic design of jobs is one of the leading causes of work-related illness, accounting for perhaps a third of employers’ costs under state workers’ compensation laws. Due to the wide variety of circumstances, however, any comprehensive standard would probably have to be complex and costly, while scientific understanding of the problem is not complete.
- Ergonomics in the Workplace: Is It Time for an OSHA Standard?
- Improper ergonomic design of jobs is one of the leading causes of work-related illness, accounting for perhaps a third of employers’ costs under state workers’ compensation laws. Due to the wide variety of circumstances, however, any comprehensive standard would probably have to be complex and costly, while scientific understanding of the problem is not complete.
- ERISA Regulation of Health Plans: Fact Sheet
- The Employee Retirement Income Security Act of 1974 (ERISA, P.L. 93-406) places the regulation of employee benefit plans (including health plans) primarily under federal jurisdiction for about 124 million people. ERISA’s treatment of health plans is both complicated and confusing. ERISA has been interpreted as dividing health plans into two groups regulated differently under the law: about 54 million people are covered by self-insured plans for which the employer, rather than an insurer, assumes the risk for paying for covered services and about 70 million people are covered by purchased insurance (according to 2000 information from the Census Bureau and the Department of Labor).
- ERISA Regulation of Health Plans: Fact Sheet
- The Employee Retirement Income Security Act of 1974 (ERISA, P.L. 93-406) places the regulation of employee benefit plans (including health plans) primarily under federal jurisdiction for about 124 million people. ERISA’s treatment of health plans is both complicated and confusing. ERISA has been interpreted as dividing health plans into two groups regulated differently under the law: about 54 million people are covered by self-insured plans for which the employer, rather than an insurer, assumes the risk for paying for covered services and about 70 million people are covered by purchased insurance (according to 2000 information from the Census Bureau and the Department of Labor).
- Family Planning: Title X of the Public Health Service Act
- This report discusses Title X of the Public Health Service Act provides support for family planning clinics, research related to family planning and population, training of family planning personnel, and development and dissemination of family planning information.
- The FDA Medical Device User Fee Program: MDUFA IV Reauthorization
- This report describes current law regarding medical device user fees, the impact of Medical Device User Fee and Modernization Act (MDUFMA) on Federal Drug Administration (FDA) review time of various medical device applications, and the agency's medical device program budget.
- FDA Regulation of Follow-On Biologics
- This report provides a brief introduction to the relevant law regarding follow-on biologics, the regulatory framework at the FDA, the scientific challenges for the FDA in considering the approval of follow-on biologics, and a description of the proposed legislation.
- FDA Regulation of Tobacco Products: A Policy and Legal Analysis
- This report examines the legislative debate over giving FDA the authority to regulate tobacco products and provides some analysis of S. 2461/H.R. 4433. It begins with an overview of the FDA’s 1996 tobacco rule that includes a summary of the agency’s arguments for asserting jurisdiction over tobacco products. That is followed by an analysis of the U.S. Supreme Court decision in FDA v. Brown & Williamson, which overturned the FDA tobacco rule. The report then reviews the 1997 proposed national tobacco settlement, which would have codified the FDA rule and given the agency explicit authority to regulate tobacco products as medical devices. It includes a discussion of the FDA provisions in the McCain tobacco bill, which was introduced and debated in the 105th Congress in an attempt to implement the proposed settlement. The final section of the report summarizes the provisions in S. 2461/H.R. 4433 and discusses some of the key issues, including preemption and the regulation of reduced-risk products.
- FDA Risk Evaluation and Mitigation Strategies (REMS): Description and Effect on Generic Drug Development
- This report provides a brief history of FDA drug regulation, describes FDA's early risk management programs, and focuses on the agency's current risk management authorities, specifically risk evaluation and mitigation strategies (REMS). The report also discusses issues that have arisen as a result of REMS, particularly the impact on generic drug competition. It does not discuss antitrust issues raised by restricted distribution systems.
- FDA Tobacco Regulation: The Family Smoking Prevention and Tobacco Control Act of 2009
- This report focuses on the Family Smoking Prevention and Tobacco Control Act. It includes a brief discussion of the contrasting views of FDA tobacco regulation held by the public health community and the industry, and provides some analysis of a number of key regulatory issues that the bill raises.
- FDA’s Authority to Ensure That Drugs Prescribed to Children Are Safe and Effective
- The Food and Drug Administration (FDA) has approved for adult use many drugs never tested in children. Yet clinicians often prescribe them for children believing that the safety and effectiveness demonstrated with adults probably reasonably transfers to younger patients. The data show that this is not always true. To encourage industry to develop drugs and medical devices for pediatric use, Congress has established three programs. The Food and Drug Administration Amendments Act of 2007 (FDAAA, P.L. 110-85) reauthorized and strengthened two laws addressing drugs—the Best Pharmaceuticals for Children Act (BPCA) of 2002 and the Pediatric Research Equity Act (PREA) of 2003—and enacted a new law addressing devices—the Pediatric Medical Device Safety and Improvement Act (PMDSIA) of 2007. The historical approach of this report allows an understanding of how and why Congress took these steps.
- Federal and State Quarantine and Isolation Authority
- This report provides an overview of federal and state public health laws as they relate to the quarantine and isolation of individuals, a discussion of constitutional issues that may be raised should individual liberties be restricted in a quarantine situation, and federalism questions that may arise where federal and state authorities overlap. In addition, the possible role of the armed forces in enforcing public health measures is discussed, specifically whether the Posse Comitatus Act would constrain any military role, and other statutory authorities that may be used for the military enforcement of health measures.
- Federal Authority to Regulate the Compounding of Human Drugs
- This report will examine the FDA's regulation of drug compounding and will discuss relevant legal authorities. The report will conclude by discussing potential limits to the FDA's authority to regulate human drug compounding.